|
1
|
Burton KA, Ashack KA and Khachemoune A:
Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and
Metastatic Disease. Am J Clin Dermatol. 17:491–508. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karia PS, Han J and Schmults CD: Cutaneous
squamous cell carcinoma: Estimated incidence of disease, nodal
metastasis, and deaths from disease in the United States, 2012. J
Am Acad Dermatol. 68:957–966. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou M, McFarland-Mancini MM, Funk HM,
Husseinzadeh N, Mounajjed T and Drew AF: Toll-like receptor
expression in normal ovary and ovarian tumors. Cancer Immunol
Immunother. 58:1375–1385. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun Y, Wu C, Ma J, Yang Y, Man X, Wu H and
Li S: Toll-like receptor 4 promotes angiogenesis in pancreatic
cancer via PI3K/AKT signaling. Exp Cell Res. 347:274–282. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong YQ, Lu CW, Zhang L, Yang J, Hameed W
and Chen W: Toll-like receptor 4 signaling promotes invasion of
hepatocellular carcinoma cells through MKK4/JNK pathway. Mol
Immunol. 68:671–683. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ye K, Wu Y, Sun Y, Lin J and Xu J: TLR4
siRNA inhibits proliferation and invasion in colorectal cancer
cells by downregulating ACAT1 expression. Life Sci. 155:133–139.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zou Y, Qin F, Chen J, Meng J, Wei L, Wu C,
Zhang Q, Wei D, Chen X, Wu H, et al: sTLR4/MD-2 complex inhibits
colorectal cancer in vitro and in vivo by targeting LPS.
Oncotarget. 7:52032–52044. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eiró N, Ovies C, Fernandez-Garcia B,
Álvarez-Cuesta CC, González L, González LO and Vizoso FJ:
Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma:
Relationship with clinicopathological characteristics and
prognosis. Arch Dermatol Res. 305:59–67. 2013. View Article : Google Scholar
|
|
9
|
Janda J, Burkett NB, Blohm-Mangone K,
Huang V, Curiel-Lewandrowski C, Alberts DS, Petricoin EF III,
Calvert VS, Einspahr J, Dong Z, et al: Resatorvid-based
Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced
NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin. Photochem
Photobiol. 92:816–825. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blohm-Mangone K, Burkett NB, Tahsin S,
Myrdal PB, Aodah A, Ho B, Janda J, McComas M, Saboda K, Roe DJ, et
al: Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks
Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice. Cancer Prev Res
(Phila). 11:265–278. 2018. View Article : Google Scholar
|
|
11
|
Iotzova-Weiss G, Freiberger SN, Johansen
P, Kamarachev J, Guenova E, Dziunycz PJ, Roux GA, Neu J and
Hofbauer GFL: TLR4 as a negative regulator of keratinocyte
proliferation. PLoS One. 12:e01856682017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Szatmary Z: Molecular biology of toll-like
receptors. Gen Physiol Biophys. 31:357–366. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mai CW, Kang YB and Pichika MR: Should a
Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to
treat cancer? TLR-4: Its expression and effects in the ten most
common cancers. Onco Targets Ther. 6:1573–1587. 2013.PubMed/NCBI
|
|
14
|
Dajon M, Iribarren K and Cremer I:
Toll-like receptor stimulation in cancer: A pro- and anti-tumor
double-edged sword. Immunobiology. 222:89–100. 2017. View Article : Google Scholar
|
|
15
|
Miller LS: Toll-like receptors in skin.
Adv Dermatol. 24:71–87. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weng H, Deng Y, Xie Y, Liu H and Gong F:
Expression and significance of HMGB1, TLR4 and NF-κB p65 in human
epidermal tumors. BMC Cancer. 13:3112013. View Article : Google Scholar
|
|
17
|
Burns EM and Yusuf N: Toll-like receptors
and skin cancer. Front Immunol. 5:1352014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yusuf N, Nasti TH, Long JA, Naseemuddin M,
Lucas AP, Xu H and Elmets CA: Protective role of Toll-like receptor
4 during the initiation stage of cutaneous chemical carcinogenesis.
Cancer Res. 68:615–622. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Karvinen S, Kosma V-MM, Tammi MII and
Tammi R: Hyaluronan, CD44 and versican in epidermal keratinocyte
tumours. Br J Dermatol. 148:86–94. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hartmann-Petersen S, Tammi RH, Tammi MI
and Kosma VM: Depletion of cell surface CD44 in nonmelanoma skin
tumours is associated with increased expression of matrix
metallopro-teinase 7. Br J Dermatol. 160:1251–1257. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Erfani E, Roudi R, Rakhshan A, Sabet MN,
Shariftabrizi A and Madjd Z: Comparative expression analysis of
putative cancer stem cell markers CD44 and ALDH1A1 in various skin
cancer subtypes. Int J Biol Markers. 31:e53–e61. 2016. View Article : Google Scholar
|
|
22
|
Senbanjo LT and Chellaiah MA: CD44: A
Multifunctional Cell Surface Adhesion Receptor Is a Regulator of
Progression and Metastasis of Cancer Cells. Front Cell Dev Biol.
5:182017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bourguignon LYW: Matrix
hyaluronan-activated CD44 signaling promotes keratinocyte
activities and improves abnormal epidermal functions. Am J Pathol.
184:1912–1919. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bourguignon LYW, Wong G, Earle CA and Xia
W: Interaction of low molecular weight hyaluronan with CD44 and
toll-like receptors promotes the actin filament-associated protein
110-actin binding and MyD88-NFκB signaling leading to
proinflammatory cytokine/chemokine production and breast tumor
invasion. Cytoskeleton (Hoboken). 68:671–693. 2011. View Article : Google Scholar
|
|
25
|
Elder DE, Massi D, Scolyer R and Willemze
R: WHO Classification of Skin Tumours Fourth Edition. WHO
Classification of Tumours. 11. IARC; Lyon: 2018
|
|
26
|
Kondo S and Aso K: Establishment of a cell
line of human skin squamous cell carcinoma in vitro. Br J Dermatol.
105:125–132. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hozumi Y, Kondo S, Shimoura T and Aso K:
Human squamous cell carcinoma from skin: Establishment and
characterization of a new cell line (HSC-5). J Dermatol.
17:143–148. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
29
|
Yanofsky VR, Mercer SE and Phelps RG:
Histopathological variants of cutaneous squamous cell carcinoma: A
review. J Skin Cancer. 2011:2108132011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Motaparthi K, Kapil JP and Velazquez EF:
Cutaneous Squamous Cell Carcinoma: Review of the Eighth Edition of
the American Joint Committee on Cancer Staging Guidelines,
Prognostic Factors, and Histopathologic Variants. Adv Anat Pathol.
24:171–194. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jacquemet G, Hamidi H and Ivaska J:
Filopodia in cell adhesion, 3D migration and cancer cell invasion.
Curr Opin Cell Biol. 36:23–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dang S, Peng Y, Ye L, Wang Y, Qian Z, Chen
Y, Wang X, Lin Y, Zhang X, Sun X, et al: Stimulation of TLR4 by
LMW-HA induces metastasis in human papillary thyroid carcinoma
through CXCR7. Clin Dev Immunol. 2013:7125612013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu L, Wang L and Chen S: Dual character of
Toll-like receptor signaling: Pro-tumorigenic effects and
anti-tumor functions. Biochim Biophys Acta. 1835:144–154. 2013.
|
|
34
|
Haricharan S and Brown P: TLR4 has a
TP53-dependent dual role in regulating breast cancer cell growth.
Proc Natl Acad Sci USA. 112:E3216–E3225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen C, Zhao S, Karnad A and Freeman JW:
The biology and role of CD44 in cancer progression: Therapeutic
implications. J Hematol Oncol. 11:642018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumours. 8th edition.
Union for International Cancer Control (UICC); Geneva: 2016
|
